A new study utilizes a novel PET radiotracer to provide the first in vivo evidence of widespread muscarinic acetylcholine M1 receptor deficits in living schizophrenia patients.
A new study utilizes a novel PET radiotracer to provide the first in vivo evidence of widespread muscarinic acetylcholine M1 receptor deficits in living schizophrenia patients.
Share this Article
Recommended